| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NM0602-594 |
| P698 | PubMed publication ID | 12042810 |
| P2093 | author name string | Lindsey M Hutt-Fletcher | |
| Corina M Borza | |||
| P2860 | cites work | An animal model for acute and persistent Epstein-Barr virus infection | Q28241858 |
| Epstein-Barr Virus Recombinant Lacking Expression of Glycoprotein gp150 Infects B Cells Normally but Is Enhanced for Infection of Epithelial Cells | Q33784012 | ||
| Epstein-Barr Virus Uses Different Complexes of Glycoproteins gH and gL To Infect B Lymphocytes and Epithelial Cells | Q33784997 | ||
| Epstein-Barr virus entry utilizing HLA-DP or HLA-DQ as a coreceptor | Q33799317 | ||
| Epstein-Barr virus gH is essential for penetration of B cells but also plays a role in attachment of virus to epithelial cells | Q33807504 | ||
| Three classes of cell surface receptors for alphaherpesvirus entry | Q34052577 | ||
| Coreceptor restriction within the HLA-DQ locus for Epstein-Barr virus infection | Q35202365 | ||
| Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes | Q35886960 | ||
| Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2 | Q36273277 | ||
| A monoclonal antibody to glycoprotein gp85 inhibits fusion but not attachment of Epstein-Barr virus. | Q36871887 | ||
| Lonely MHC molecules seeking immunogenic peptides for meaningful relationships. | Q40380611 | ||
| Epstein-Barr virus glycoprotein gp85 associates with the BKRF2 gene product and is incompletely processed as a recombinant protein | Q41535520 | ||
| Direct Visualization of Antigen-specific CD8+T Cells during the Primary Immune Response to Epstein-Barr Virus In Vivo | Q41764334 | ||
| Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes. | Q42123661 | ||
| Specific antimononuclear phagocyte monoclonal antibodies. Application to the purification of dendritic cells and the tissue localization of macrophages | Q42936592 | ||
| Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis | Q43974065 | ||
| Cellular expression of alphaherpesvirus gD interferes with entry of homologous and heterologous alphaherpesviruses by blocking access to a shared gD receptor | Q44757579 | ||
| Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines | Q45797211 | ||
| Epstein-Barr virus infection and replication in a human epithelial cell system | Q45880200 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Epstein–Barr virus | Q6900 |
| P304 | page(s) | 594-599 | |
| P577 | publication date | 2002-06-01 | |
| P1433 | published in | Nature medicine | Q1633234 |
| P1476 | title | Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus | |
| P478 | volume | 8 |
| Q31117844 | A Role for the Nucleosome Assembly Proteins TAF-Iβ and NAP1 in the Activation of BZLF1 Expression and Epstein-Barr Virus Reactivation |
| Q54216760 | A Screen for Epstein-Barr Virus Proteins that Inhibit the DNA Damage Response Reveals a Novel Histone Binding Protein |
| Q41103972 | A Viral Pilot for HCMV Navigation? |
| Q59357534 | A bacterial genotoxin causes virus reactivation and genomic instability in Epstein-Barr virus infected epithelial cells pointing to a role of co-infection in viral oncogenesis |
| Q34781581 | A case of Epstein-Barr Virus (EBV)-associated thymic carcinoid and investigation of existence of EBV-infected cells in thymus and thymic tumors |
| Q35034283 | A gammaherpesvirus uses alternative splicing to regulate its tropism and its sensitivity to neutralization. |
| Q59357522 | A genome-wide screen of Epstein-Barr virus proteins that modulate host SUMOylation identifies a SUMO E3 ligase conserved in herpesviruses |
| Q36532893 | A soluble form of Epstein-Barr virus gH/gL inhibits EBV-induced membrane fusion and does not function in fusion |
| Q35378089 | A viral regulator of glycoprotein complexes contributes to human cytomegalovirus cell tropism. |
| Q27319763 | A virtual look at Epstein-Barr virus infection: biological interpretations |
| Q37682377 | A yeast-based assay identifies drugs that interfere with immune evasion of the Epstein-Barr virus |
| Q38328774 | Activation of CD21 and CD23 gene expression by Kaposi's sarcoma-associated herpesvirus RTA |
| Q57093333 | Air-Liquid Interface System To Understand Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma |
| Q90356751 | Alcelaphine herpesvirus 1 genes A7 and A8 regulate viral spread and are essential for malignant catarrhal fever |
| Q45372116 | Alternating Host Cell Tropism Shapes the Persistence, Evolution and Coexistence of Epstein–Barr Virus Infections in Human |
| Q52317335 | An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus. |
| Q36171933 | An Epstein-Barr Virus (EBV) Mutant with Enhanced BZLF1 Expression Causes Lymphomas with Abortive Lytic EBV Infection in a Humanized Mouse Model |
| Q24649032 | An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival |
| Q37033353 | Analysis of Epstein-Barr virus glycoprotein B functional domains via linker insertion mutagenesis |
| Q36700342 | Analysis of Epstein-Barr virus infection models in a series of pediatric carriers from a developing country |
| Q35633651 | Analysis of Epstein-Barr virus reservoirs in paired blood and breast cancer primary biopsy specimens by real time PCR. |
| Q35101331 | Antibodies to gp350/220 enhance the ability of Epstein-Barr virus to infect epithelial cells |
| Q28542501 | Assembly and architecture of the EBV B cell entry triggering complex |
| Q37221472 | Associations between EBV and CMV Seropositivity, Early Exposures, and Gut Microbiota in a Prospective Birth Cohort: A 10-Year Follow-up |
| Q48507544 | B cells in the pathogenesis of primary Sjögren syndrome |
| Q45728528 | B-lymphocyte subpopulations are equally susceptible to Epstein-Barr virus infection, irrespective of immunoglobulin isotype expression |
| Q35948061 | Binding-site interactions between Epstein-Barr virus fusion proteins gp42 and gH/gL reveal a peptide that inhibits both epithelial and B-cell membrane fusion. |
| Q35017865 | Biological aspects of Epstein-Barr virus (EBV)-infected lymphocytes in chronic active EBV infection and associated malignancies |
| Q37310520 | Biomolecular markers in cancer of the tongue |
| Q34542953 | Bovine herpesvirus 4 glycoprotein B is indispensable for lytic replication and irreplaceable by VSVg |
| Q37839350 | Cell entry of enveloped viruses. |
| Q37713781 | Cell-surface expression of a mutated Epstein-Barr virus glycoprotein B allows fusion independent of other viral proteins |
| Q74221401 | Cell-switching and kissing |
| Q36253674 | Characterization of EBV gB indicates properties of both class I and class II viral fusion proteins |
| Q42572343 | Characterization of a discontinuous neutralizing epitope on glycoprotein B of human cytomegalovirus |
| Q38307961 | Characterization of the Epstein-Barr virus glycoprotein BMRF-2. |
| Q42631734 | Characterization of the Herpesvirus saimiri Orf51 protein |
| Q36423984 | Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells. |
| Q37232892 | Cleavage and secretion of Epstein-Barr virus glycoprotein 42 promote membrane fusion with B lymphocytes |
| Q38812531 | Comparative Mutagenesis of Pseudorabies Virus and Epstein-Barr Virus gH Identifies a Structural Determinant within Domain III of gH Required for Surface Expression and Entry Function |
| Q37123419 | Comparative analysis of gO isoforms reveals that strains of human cytomegalovirus differ in the ratio of gH/gL/gO and gH/gL/UL128-131 in the virion envelope |
| Q35463816 | Comparison of humoral immune responses to Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus using a viral proteome microarray |
| Q24541318 | Compartmentalization and transmission of multiple epstein-barr virus strains in asymptomatic carriers |
| Q36676670 | Compatibility of the gH homologues of Epstein-Barr virus and related lymphocryptoviruses |
| Q55340860 | Continuous DNA replication is required for late gene transcription and maintenance of replication compartments in gammaherpesviruses. |
| Q34302078 | Contribution of C/EBP proteins to Epstein-Barr virus lytic gene expression and replication in epithelial cells |
| Q27666358 | Crystal structure of the Epstein-Barr virus (EBV) glycoprotein H/glycoprotein L (gH/gL) complex |
| Q33987451 | Deletion of gpUL132, a structural component of human cytomegalovirus, results in impaired virus replication in fibroblasts |
| Q33782152 | Dendritic cells during Epstein Barr virus infection |
| Q35941628 | Deregulation of the cell cycle by the Epstein-Barr virus |
| Q40874243 | Differential cellular localization of Epstein-Barr virus and human cytomegalovirus in the colonic mucosa of patients with active or quiescent inflammatory bowel disease |
| Q36799017 | Differential protein partitioning within the herpesvirus tegument and envelope underlies a complex and variable virion architecture |
| Q33563969 | EBNA1 regulates cellular gene expression by binding cellular promoters |
| Q38596344 | EBV Persistence--Introducing the Virus |
| Q38912277 | EBV glycoproteins: where are we now? |
| Q61810399 | EBV miR-BART10-3p Promotes Cell Proliferation and Migration by Targeting DKK1 |
| Q44092146 | EBV stimulates TLR‐ and autophagy‐dependent pathways and impairs maturation in plasmacytoid dendritic cells: Implications for viral immune escape |
| Q47576936 | Early Epstein-Barr Virus Genomic Diversity and Convergence toward the B95.8 Genome in Primary Infection |
| Q34991458 | Early activation of teleost B cells in response to rhabdovirus infection |
| Q40047749 | Efficacy of recombinant adenovirus expressing a fusion gene from GM-CSF and Epstein-Barr virus LMP2A in a mouse tumor model |
| Q34581330 | Efficient replication of Epstein-Barr virus in stratified epithelium in vitro |
| Q59357598 | Elevated antibodies against Epstein-Barr virus among individuals predicted to carry nasopharyngeal carcinoma susceptibility variants |
| Q36403664 | Endogenous human cytomegalovirus gB is presented efficiently by MHC class II molecules to CD4+ CTL |
| Q38123994 | Entry of Herpesviruses into Cells: The Enigma Variations |
| Q47239784 | Ephrin receptor A2 is an epithelial cell receptor for Epstein-Barr virus entry |
| Q38667123 | Epigenetic Alterations in Epstein-Barr Virus-Associated Diseases |
| Q35140295 | Epithelial Cell Retention of Transcriptionally Active, P3HR-1-Derived Heterogeneous Epstein-Barr Virus DNA with Concurrent Loss of Parental Virus |
| Q90481053 | Epithelial cell infection by Epstein-Barr virus |
| Q38257974 | Epstein- Barr Virus: Clinical and Epidemiological Revisits and Genetic Basis of Oncogenesis |
| Q38076138 | Epstein-Barr Virus (EBV)-associated gastric carcinoma |
| Q36481462 | Epstein-Barr Virus MicroRNA miR-BART20-5p Suppresses Lytic Induction by Inhibiting BAD-Mediated caspase-3-Dependent Apoptosis |
| Q26775442 | Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developments |
| Q24562972 | Epstein-Barr virus (EBV) SM protein induces and recruits cellular Sp110b to stabilize mRNAs and enhance EBV lytic gene expression |
| Q59351211 | Epstein-Barr virus BORF2 inhibits cellular APOBEC3B to preserve viral genome integrity |
| Q56891093 | Epstein-Barr virus DNA modulates regulatory T-cell programming in addition to enhancing interleukin-17A production via Toll-like receptor 9 |
| Q34261764 | Epstein-Barr virus EBNA1 protein regulates viral latency through effects on let-7 microRNA and dicer |
| Q59355883 | Epstein-Barr virus activates F-box protein FBXO2 to limit viral infectivity by targeting glycoprotein B for degradation |
| Q40048502 | Epstein-Barr virus and gastric carcinoma--viral carcinogenesis through epigenetic mechanisms. |
| Q42220211 | Epstein-Barr virus associated peri-implantitis: a split-mouth study. |
| Q35947541 | Epstein-Barr virus entry |
| Q34593777 | Epstein-Barr virus glycoprotein gB and gHgL can mediate fusion and entry in trans, and heat can act as a partial surrogate for gHgL and trigger a conformational change in gB. |
| Q40478188 | Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class II immune evasion. |
| Q37449248 | Epstein-Barr virus in human malignancy: a special reference to Epstein-Barr virus associated gastric carcinoma |
| Q40128636 | Epstein-Barr virus induces MCP-1 secretion by human monocytes via TLR2. |
| Q38249886 | Epstein-Barr virus infection and persistence in nasopharyngeal epithelial cells |
| Q24561854 | Epstein-Barr virus infection in ex vivo tonsil epithelial cell cultures of asymptomatic carriers |
| Q38260827 | Epstein-Barr virus infection mechanisms |
| Q24294987 | Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells |
| Q40155828 | Epstein-Barr virus inhibits Kaposi's sarcoma-associated herpesvirus lytic replication in primary effusion lymphomas |
| Q34717579 | Epstein-Barr virus shed in saliva is high in B-cell-tropic glycoprotein gp42. |
| Q35115666 | Epstein-Barr virus type 2 latently infects T cells, inducing an atypical activation characterized by expression of lymphotactic cytokines. |
| Q35110900 | Epstein-Barr virus-associated T-/natural killer cell lymphoproliferative diseases |
| Q26824570 | Epstein-Barr virus-associated lymphoid malignancies: the expanding spectrum of hematopoietic neoplasms |
| Q35076846 | Epstein-Barr virus-recent advances |
| Q29617969 | Epstein-Barr virus: 40 years on |
| Q35218805 | Epstein-barr virus in gastro-esophageal adenocarcinomas - single center experiences in the context of current literature |
| Q36315825 | Evidence for a multiprotein gamma-2 herpesvirus entry complex. |
| Q39685222 | Evidence for early infection of nonneoplastic natural killer cells by Epstein-Barr virus |
| Q54665134 | Ex vivo modeling of oral HIV transmission in human palatine tonsil. |
| Q35738744 | Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disorders |
| Q84590160 | FR-like EBNA1 binding repeats in the human genome |
| Q36362169 | Features of Human Herpesvirus-6A and -6B Entry |
| Q90600086 | First Impressions-the Potential of Altering Initial Host-Virus Interactions for Rational Design of Herpesvirus Vaccine Vectors |
| Q35622700 | Fusing structure and function: a structural view of the herpesvirus entry machinery |
| Q35599292 | Fusion of Epstein-Barr Virus with Epithelial Cells Can Be Triggered by αvβ5 in Addition to αvβ6 and αvβ8, and Integrin Binding Triggers a Conformational Change in Glycoproteins gHgL |
| Q37453542 | Fusion of epithelial cells by Epstein-Barr virus proteins is triggered by binding of viral glycoproteins gHgL to integrins alphavbeta6 or alphavbeta8. |
| Q38411353 | Genetic variability of cytomegalovirus glycoprotein O in hematopoietic stem cell transplant recipients |
| Q33925373 | Genome-wide analysis of wild-type Epstein-Barr virus genomes derived from healthy individuals of the 1,000 Genomes Project |
| Q37065966 | Global Mapping of O-Glycosylation of Varicella Zoster Virus, Human Cytomegalovirus, and Epstein-Barr Virus. |
| Q34575025 | Glycoprotein L disruption reveals two functional forms of the murine gammaherpesvirus 68 glycoprotein H. |
| Q33910634 | Glycoprotein L sets the neutralization profile of murid herpesvirus 4. |
| Q36893722 | HCMV gH/gL/UL128-131 interferes with virus entry into epithelial cells: evidence for cell type-specific receptors |
| Q33798083 | HCMV spread and cell tropism are determined by distinct virus populations |
| Q34285628 | Herpes virus fusion and entry: a story with many characters. |
| Q35217323 | Herpesvirus entry: an update |
| Q37438944 | Herpesvirus transport to the nervous system and back again. |
| Q34273467 | Host cell-dependent expression of latent Epstein-Barr virus genomes: regulation by DNA methylation |
| Q24635001 | Human Herpesvirus 6 Glycoprotein Complex Formation Is Required for Folding and Trafficking of the gH/gL/gQ1/gQ2 Complex and Its Cellular Receptor Binding |
| Q47549698 | Human MHC-II with Shared Epitope Motifs Are Optimal Epstein-Barr Virus Glycoprotein 42 Ligands-Relation to Rheumatoid Arthritis. |
| Q34609654 | Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay |
| Q33649006 | Human cytomegalovirus TR strain glycoprotein O acts as a chaperone promoting gH/gL incorporation into virions but is not present in virions |
| Q35803399 | Human cytomegalovirus US2 causes similar effects on both major histocompatibility complex class I and II proteins in epithelial and glial cells |
| Q34301880 | Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion |
| Q36974741 | Human cytomegalovirus glycoproteins gB and gH/gL mediate epithelial cell-cell fusion when expressed either in cis or in trans |
| Q36289031 | Human cytomegalovirus uses two distinct pathways to enter retinal pigmented epithelial cells |
| Q38923409 | Hypermethylation of the interferon regulatory factor 5 promoter in Epstein-Barr virus-associated gastric carcinoma |
| Q92152903 | Identification of ARKL1 as a Negative Regulator of Epstein-Barr Virus Reactivation |
| Q45325147 | Identification of Epstein-Barr Virus in the Human Placenta and Its Pathologic Characteristics. |
| Q37041507 | Immune escape by Epstein-Barr virus associated malignancies |
| Q54263338 | Immune responses to an early lytic cytomegalovirus antigen in systemic lupus erythematosus patients: T-cell responses, cytokine secretions and antibody status. |
| Q61444466 | Immunoinformatic and systems biology approaches to predict and validate peptide vaccines against Epstein-Barr virus (EBV) |
| Q38778924 | Immunotherapy against cancer-related viruses |
| Q35665954 | Important but Differential Roles for Actin in Trafficking of Epstein-Barr Virus in B Cells and Epithelial Cells |
| Q34348276 | In vivo function of a gammaherpesvirus virion glycoprotein: influence on B-cell infection and mononucleosis |
| Q26783692 | Infectious Mononucleosis |
| Q41931840 | Inhibition of EBV-mediated membrane fusion by anti-gHgL antibodies. |
| Q37823103 | Integrins as triggers of Epstein-Barr virus fusion and epithelial cell infection |
| Q36161320 | Interference with T cell receptor–HLA-DR interactions by Epstein–Barr virus gp42 results in reduced T helper cell recognition |
| Q35023947 | Investigation of the function of the putative self-association site of Epstein-Barr virus (EBV) glycoprotein 42 (gp42). |
| Q36167487 | Involvement of the Epstein-Barr virus in the nasopharyngeal carcinoma pathogenesis. |
| Q34532370 | Latent membrane protein 1 inhibits Epstein-Barr virus lytic cycle induction and progress via different mechanisms. |
| Q40628193 | Latent membrane protein 1 of Epstein-Barr virus stimulates processing of NF-kappa B2 p100 to p52. |
| Q39226546 | Linkage of human cytomegalovirus glycoprotein gO variant groups identified from worldwide clinical isolates with gN genotypes, implications for disease associations and evidence for N-terminal sites of positive selection |
| Q41788529 | Lipid rafts of primary endothelial cells are essential for Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8-induced phosphatidylinositol 3-kinase and RhoA-GTPases critical for microtubule dynamics and nuclear delivery of viral DNA but dis |
| Q45087853 | Low incidence of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in Tianjin, northern China |
| Q38189401 | Lymphoblastoid Cell lines: a Continuous in Vitro Source of Cells to Study Carcinogen Sensitivity and DNA Repair |
| Q34120826 | Mapping the N-terminal residues of Epstein-Barr virus gp42 that bind gH/gL by using fluorescence polarization and cell-based fusion assays |
| Q35038210 | Membrane anchoring of Epstein-Barr virus gp42 inhibits fusion with B cells even with increased flexibility allowed by engineered spacers |
| Q34059350 | MicroRNA miR-BART20-5p stabilizes Epstein-Barr virus latency by directly targeting BZLF1 and BRLF1 |
| Q42097616 | Modeling the dynamics of virus shedding into the saliva of Epstein-Barr virus positive individuals |
| Q102379204 | Molecular basis of EphA2 recognition by gHgL from gammaherpesviruses |
| Q45352227 | Molecular diagnosis of Epstein–Barr virus infections |
| Q37730255 | Murine gammaherpesvirus 68 lacking gp150 shows defective virion release but establishes normal latency in vivo. |
| Q34151639 | Mutational analyses of Epstein-Barr virus glycoprotein 42 reveal functional domains not involved in receptor binding but required for membrane fusion |
| Q35149283 | Mutational analysis of the HLA class II interaction with Epstein-Barr virus glycoprotein 42. |
| Q33930429 | Mutations of Epstein-Barr virus gH that are differentially able to support fusion with B cells or epithelial cells |
| Q28472086 | Mutual inhibition between Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus lytic replication initiators in dually-infected primary effusion lymphoma |
| Q34426495 | Myeloid infection links epithelial and B cell tropisms of Murid Herpesvirus-4. |
| Q35557176 | Non-redundant and redundant roles of cytomegalovirus gH/gL complexes in host organ entry and intra-tissue spread. |
| Q36055637 | Nonmuscle myosin heavy chain IIA mediates Epstein-Barr virus infection of nasopharyngeal epithelial cells |
| Q37745980 | Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice |
| Q41908850 | Nucleophosmin contributes to the transcriptional activation function of the Epstein-Barr virus EBNA1 protein |
| Q35874385 | Opportunistic DNA Recombination With Epstein-Barr Virus at Sites of Control Region Rearrangements Mediating JC Virus Neurovirulence |
| Q91773682 | Overexpression of Epstein-Barr virus-encoded latent membrane protein-1 (LMP-1) in oral squamous cell carcinoma |
| Q40286804 | Ovine herpesvirus 2 infection in American bison: virus and host dynamics in the development of sheep-associated malignant catarrhal fever. |
| Q60960757 | Pathogen at the Gates: Human Cytomegalovirus Entry and Cell Tropism |
| Q38346756 | Pathogen manipulation of B cells: the best defence is a good offence |
| Q28285357 | Pathogenesis of gammaherpesvirus infections |
| Q39418680 | Periodontopathogen and Epstein-Barr Virus-Associated Periapical Periodontitis May Be the Source of Retrograde Infectious Peri-Implantitis |
| Q37822568 | Possible role of EBV in breast cancer and other unusually EBV-associated cancers |
| Q24645297 | Priming of protective T cell responses against virus-induced tumors in mice with human immune system components |
| Q24597706 | Progress and Problems in Understanding and Managing Primary Epstein-Barr Virus Infections |
| Q54593236 | Recent advances in CMV tropism, latency, and diagnosis during aging. |
| Q37146126 | Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases |
| Q40471319 | Regulation of expression of the Epstein-Barr virus BamHI-A rightward transcripts. |
| Q34598541 | Resting B cells as a transfer vehicle for Epstein-Barr virus infection of epithelial cells |
| Q57176933 | Role of Epstein-Barr Virus in the Pathogenesis of Head and Neck Cancers and Its Potential as an Immunotherapeutic Target |
| Q35857323 | Routine Epstein-Barr virus diagnostics from the laboratory perspective: still challenging after 35 years |
| Q36694106 | Secreted Oral Epithelial Cell Membrane Vesicles Induce Epstein-Barr Virus Reactivation in Latently Infected B Cells. |
| Q40519563 | Shedding of ovine herpesvirus 2 in sheep nasal secretions: the predominant mode for transmission |
| Q35101434 | Soluble Epstein-Barr virus glycoproteins gH, gL, and gp42 form a 1:1:1 stable complex that acts like soluble gp42 in B-cell fusion but not in epithelial cell fusion |
| Q26752331 | Structural and Mechanistic Insights into the Tropism of Epstein-Barr Virus |
| Q37500979 | Structural basis for Epstein-Barr virus host cell tropism mediated by gp42 and gHgL entry glycoproteins. |
| Q27653795 | Structure of Epstein-Barr Virus Glycoprotein 42 Suggests a Mechanism for Triggering Receptor-Activated Virus Entry |
| Q38739747 | TAX1BP1 downregulation by EBV-miR-BART15-3p enhances chemosensitivity of gastric cancer cells to 5-FU. |
| Q35598260 | Telomerase activity impacts on Epstein-Barr virus infection of AGS cells |
| Q36945442 | The BDLF3 gene product of Epstein-Barr virus, gp150, mediates non-productive binding to heparan sulfate on epithelial cells and only the binding domain of CD21 is required for infection |
| Q36414572 | The Cellular Ataxia Telangiectasia-Mutated Kinase Promotes Epstein-Barr Virus Lytic Reactivation in Response to Multiple Different Types of Lytic Reactivation-Inducing Stimuli |
| Q37417371 | The Cytoplasmic Tail Domain of Epstein-Barr Virus gH Regulates Membrane Fusion Activity through Altering gH Binding to gp42 and Epithelial Cell Attachment |
| Q59326239 | The EBV-DNA Can be Used as a Diagnostic and Follow-up Parameter of the Rhinopharyngeal Tumors in the Non-Endemic Population of the Western Sicily |
| Q92964666 | The Epstein-Barr Virus BMRF1 Protein Activates Transcription and Inhibits the DNA Damage Response by Binding NuRD |
| Q34261421 | The Epstein-Barr virus (EBV) glycoprotein B cytoplasmic C-terminal tail domain regulates the energy requirement for EBV-induced membrane fusion |
| Q35856872 | The Incubation Period of Primary Epstein-Barr Virus Infection: Viral Dynamics and Immunologic Events |
| Q38994418 | The Long and Complicated Relationship between Epstein-Barr Virus and Epithelial Cells |
| Q33355983 | The Murid Herpesvirus-4 gL regulates an entry-associated conformation change in gH. |
| Q33984291 | The amino terminus of Epstein-Barr virus glycoprotein gH is important for fusion with epithelial and B cells |
| Q34485104 | The bovine herpesvirus 4 Bo10 gene encodes a nonessential viral envelope protein that regulates viral tropism through both positive and negative effects |
| Q34593942 | The conserved disulfide bond within domain II of Epstein-Barr virus gH has divergent roles in membrane fusion with epithelial cells and B cells |
| Q28752465 | The dynamics of EBV shedding implicate a central role for epithelial cells in amplifying viral output |
| Q34624363 | The infectious kiss: newly infected B cells deliver Epstein-Barr virus to epithelial cells |
| Q40340374 | The m74 gene product of murine cytomegalovirus (MCMV) is a functional homolog of human CMV gO and determines the entry pathway of MCMV. |
| Q33724362 | The murine gammaherpesvirus 68 ORF27 gene product contributes to intercellular viral spread |
| Q38253914 | The role of Epstein-Barr virus in epithelial malignancies |
| Q38440804 | The role of Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma |
| Q33319277 | Tonsilar NK cells restrict B cell transformation by the Epstein-Barr virus via IFN-gamma |
| Q42641908 | UL74 of human cytomegalovirus contributes to virus release by promoting secondary envelopment of virions |
| Q43491998 | UL74 of human cytomegalovirus reduces the inhibitory effect of gH-specific and gB-specific antibodies |
| Q64254754 | Unravelling the first key steps in equine herpesvirus type 5 (EHV5) pathogenesis using ex vivo and in vitro equine models |
| Q35903203 | Update on herpesvirus amplicon vectors |
| Q40409705 | Use of a BJAB-derived cell line for isolation of human herpesvirus 8 |
| Q37730214 | Use of gHgL for attachment of Epstein-Barr virus to epithelial cells compromises infection |
| Q41750200 | Using proximity biotinylation to detect herpesvirus entry glycoprotein interactions: Limitations for integral membrane glycoproteins |
| Q50955999 | Viral Entry |
| Q38128634 | Virus induced inflammation and cancer development |
| Q35206910 | Virus interactions with mucosal surfaces: alternative receptors, alternative pathways |
| Q27481175 | Viruses and human cancer |
| Q39703319 | α-Helix peptides designed from EBV-gH protein display higher antigenicity and induction of monocyte apoptosis than the native peptide. |
| Q28084340 | Infectious mononucleosis. |
Search more.